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We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients
with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4
toxicity were seen, with no toxic deaths. Objective response rates were CR/PR¼53%; NC¼34.7%; PD¼12.2%. Median time to
progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the
conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.
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The fortnightly infusional LV5FU2 or ‘de Gramont’ regimen of
fluorouracil (FU) and leucovorin (LV) is less toxic than bolus FU/
LV, but gives a higher response rate and longer progression-free
survival (de Gramont et al, 1997). It has therefore been used as the
partner for other drugs in combination regimens (de Gramont et al,
2000; Douillard et al, 2000). ‘FOLFOX4’–the combination of
LV5FU2 with oxaliplatin 85mgm
 2–was recently compared to the
US standard bolus irinotecan, FU and folinic acid regimen (IFL) in
NCCTG trial N9741, and showed improved survival and toxicity
(Goldberg et al, 2002). It is therefore now accepted by the FDA as a
standard comparator regimen for licensing trials in advanced
colorectal cancer.
Regimens based on LV5FU2 are, however, time consuming,
cumbersome and expensive (Ross et al, 1998). Their benefits are,
therefore, partly offset by the demands that they place on patients
and the health-care system. Two strategies are being investigated
to overcome these problems (1) to replace the complex 2-day
sequence of FU and LV infusions and injections with a simplified
infusion administered at home using a portable pump; or (2) to
replace LV5FU2 altogether, using the oral prodrug, capecitabine.
We recently published pilot data on an ‘Oxaliplatin þ Modified
de Gramont’ regimen (OxMdG). In our single centre study, this
new regimen demonstrated exceptional activity as first-line
treatment, and was also well tolerated and convenient (Cheeseman
et al, 2002). We now present data from a prospective multicentre
phase 2 study of a further 55 patients receiving the same OxMdG
schedule as first-line treatment for advanced colorectal cancer.
PATIENTS AND METHODS
Following Multicentre Research Ethics Committee approval, we
recruited 56 patients at 14 institutions between January 2000 and
July 2001. All patients had inoperable metastatic colorectal cancer
and had not received prior chemotherapy for metastatic disease.
Other eligibility criteria were: WHO performance status 0–2;
bilirubin o50mmoll
 1l; ALP and transaminases o3  upper
limit of normal; WBC43 10
9l
 1; neutrophils 41.5 10
9l
 1;
platelets4100 10
9l
 1; GFR (Cockcoft estimate or EDTA clear-
ance) 460ml min
 1. Contraception was required for women of
child-bearing potential. Written informed consent was obtained
from all patients prior to study entry.
Treatment
Semipermanent venous access was established with a single-lumen
Hickman line, Portacath, or PICC line according to local practice.
Low-dose anticoagulation with warfarin (10mg on the day of Received 23 January 2003; revised 23 May 2003; accepted 29 June 2003
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linsertion and 1mg daily thereafter) was recommended (Bern et al,
1990). The OxMdG regimen was given every 14 days as follows.
Intravenous bolus dexamethasone 8mg and granisetron 1mg
were given prior to chemotherapy. Then, oxaliplatin 85mgm
 2
was given concurrently with l-leucovorin 175mg (flat-rate), via a
Y-connector, as a 2h i.v. infusion. Each drug was diluted in 250ml
5% dextrose, to avoid mixing oxaliplatin with saline. Next, FU was
given at 400mgm
 2 i.v. bolus over 5min, followed by 2400mgm
 2
as a 46h FU infusion using a disposable elastometric pump (Baxter
LV5
s) or equivalent device. Oral dexamethasone 4mg t.d.s. was
given on day 2, b.d. on day 3 and o.d. on day 4.
Treatment was initiated in the chemotherapy day-unit and
continued at home. After the infusion the line was flushed by the
patient’s community nurse; Hickman and PICC lines were also
flushed weekly between treatments. Where necessary, prior to
establishing central venous access, the 46h FU infusion was given
in 2000ml saline via a peripheral cannula, as an inpatient.
Evaluation of response and duration of treatment
Blood tests and clinical evaluation were performed each fortnight,
prior to treatment. Toxicity was evaluated using NCI CTC criteria
(version 2). In particular, patients were monitored for peripheral
sensory symptoms. If patients developed paraesthesia which
persisted for 14 days after oxaliplatin administration, became
painful, or caused functional impairment, oxaliplatin was omitted
from the schedule but the other drugs were continued. Other dose
adjustments followed standard guidelines: doses of both cytotoxic
drugs were reduced by 20% after grade 3–4 toxicity, or after 2
delays for grade 2 toxicity.
Tumour marker assays were repeated every 4 weeks and CT
scans (or other relevant imaging) every 12 weeks. The response to
chemotherapy was assessed by RECIST criteria (Therasse et al,
2000), except that confirmatory scans 4 weeks after a response
were not required.
The plan was to deliver six treatment cycles at 2-week intervals
followed by response evaluation, then a further six cycles for
patients with stable or responding disease. Treatment beyond 12
cycles could be offered the clinician’s discretion, but this was not
normal practice in most participating institutions.
RESULTS
Treatment delivery and toxicity
In all, 56 patients were registered, but one did not receive
chemotherapy because of clinical deterioration soon after registra-
tion. Baseline characteristics of the 55 patients treated are
summarised in Table 1; all but three had measurable disease by
RECIST criteria.
A total of 479 cycles of OxMdG were delivered (median 10 cycles
per patient). In all, 62 (13%) of these cycles were delayed for
toxicity, most commonly haematological: 36 (8%) for neutropenia
and 21 (4%) for thrombocytopenia. Only three cycles (o1%) were
delayed for diarrhoea, three cycles for venous line infection and
one because of neutropenic sepsis. In one patient the cycle was
extended to three-weekly (out-with protocol) because of persistent
low blood counts.
Five patients (9%) required omission of oxaliplatin from the
schedule for sensory symptoms occurring at cycles 7–11, and one
patient (2%) because of an allergic reaction at cycle 9. In all, 25
(45%) patients underwent dose reduction at some point during
their treatment, most commonly because of grade 3 neutropenia or
thrombocytopenia.
Toxicity per cycle (NCI CTC, version 2) occurring during the
first six cycles is shown in Table 2. The maximum haematological
toxicity experienced at any point in treatment was grade 3 or 4 in
20% patients and grade 2 or less in the remaining 80% patients. No
grade 4 non-haematological toxicity was seen. The maximum non-
haematological toxicity experienced was grade 3 in 16 patients
(29%), although in 6 cases this was lethargy, scoring of which is
subjective. Five (9%) patients experienced grade 3 diarrhoea, three
(5%) had grade 3 nausea or vomiting and one (2%) had grade 3
mucositis. Overall, 23 patients (42%) experienced a grade 3–4
haematological or non-haematological event at some point in
treatment.
Grade 1 or transient grade 2 neuropathy was common,
occurring in 55% of patients during the first six cycles, but at
some point in treatment in 78% of patients.
Antitumour activity
In all, 52 patients had measurable disease at the outset. Three were
withdrawn from the trial: one declined further treatment after
cycle 2 following an episode of Campylobacter sp. diarrhoea, one
was withdrawn after cycle 2 because of a pelvic abscess requiring
surgery; the third after cycle 4 because of an ischaemic leg
requiring embolectomy, which was complicated by a postoperative
myocardial infarct. These three patients are not included in the
response rate analysis, but are included in the intent-to-treat
survival analysis.
Of the remaining 49 patients, four had a radiological complete
response (8.1%) and 22 (44.9%) a partial response, giving an
overall response rate of 53%. A further 17 (34.7%) had stable
disease for at least 12 weeks, so a total of 87% of patients had some
evidence of anticancer activity. Only six (12.2%) patients had
disease progression as their only response.
Apart from the planned end of treatment, the reason for
stopping treatment was given as progressive disease in 13 patients
and toxicity in six (usually grade 3 lethargy).
Table 1 Patient characteristics
Number 55
Sex (m:f) 38:17
Age: median (range) (years) 59 (23–79)
Performance status
0 24 (43.6%)
1 28 (50.9%)
2 3 (5.4%)
Primary site
Colon 28
a
Rectum 27
Previous treatment
Adjuvant 5FU/FA 14
Pre- or post-op radiotherapy 8
Marimastat 1
aIncluding one appendiceal carcinoma.
Table 2 Toxicity per cycle of OxMdG, cycles 1–6
All grades (%) Grade 3–4 (%)
Lethargy 95 (31) 9 (3)
Nausea 45 (14) 3 (1)
Vomiting 30 (10) 4 (1)
Diarrhoea 86 (28) 7 (2)
Mucositis 52 (17) 1 (o1)
Skin (HFS) 43 (14) 0
Neuropathy 167 (55) 0
Neutropenia 36 (12) 9 (3)
Thrombocytopenia 64 (21) 0
N¼304 cycles.
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lSurvival
Time to progression (TTP) and overall survival (OS) were
calculated for all 55 patients (Figures 1 and 2). Median TTP was
8.3 months (range 1.8–29.8months) and median OS was 14.5
months (range 2.6–31.1months). In all, 62% of patients were alive
1 year after registration.
In total, 25 (45%) patients received further anticancer treatment
after completion of the trial protocol. Four underwent resection of
metastases: two hemihepatectomies, one resection of abdominal
wall disease and one resection of bilateral Krukenberg tumours.
One of the patients undergoing liver surgery was found to have had
a pathological complete response. In all, 10 (18%) patients received
radiotherapy, and 22 (40%) received second-line chemotherapy,
usually including mitomycin or irinotecan.
At 18 months after study closure, and with median 35 months
potential follow-up, 11 (20%) patients remain alive. In 43 patients
the cause of death was progressive disease; the remaining patient
had a pulmonary embolism within 30 days of the final cycle of
treatment.
DISCUSSION
We recently reported a single-institution phase II trial of OxMdG
in 62 patients with advanced colorectal cancer. That trial included
24 assessable patients who received the regimen as first-line
therapy for metastatic colorectal cancer, whose case-notes and
scans were reviewed by an independent external radiologist and
oncologist; 72% had RECIST complete or partial responses,
confirmed by a second scan; a further 8% had partial responses
that were not confirmed by a second scan (Cheeseman et al, 2002).
That high response rate (72% confirmed; 80% confir-
medþunconfirmed) was markedly higher than, although statisti-
cally consistent with, other first-line trials of FU/FA with
oxaliplatin (De Gramont et al, 2000; Tournigand et al, 2001;
Goldberg et al, 2003). Nevertheless, this high response rate was
achieved in a single centre trial; also, we had some concerns that,
despite low rates of grade 3 and 4 toxicity, there were two (3.2%)
treatment-related deaths.
The current trial was, therefore, initiated to see whether the high
activity of the regimen could be reproduced in a multicentre
setting, and to further investigate its safety prior to use in a phase
III trial. We have confirmed that OxMdG is well-tolerated, with
extremely low levels of grade 3 and 4 toxicity, and no deaths were
attributable to chemotherapy. The one death not attributed to
disease progression occurred after the discontinuation of treat-
ment but within 30 days of the last cycle, and was due to a
pulmonary embolism. Importantly, although the objective re-
sponse rate of 53% is lower than in our previous study, this has
been achieved in a larger group of patients as part of a multicentre
study. Moreover, this is in line with other experiences as shown in
Table 3 which summarises the results of our previous study, those
from FOLFOX4 (de Gramont et al, 2000) and FOLFOX6
(Tournigand et al, 2001).
These data suggest that OxMdG is a more convenient but equally
efficacious and well tolerated alternative to FOLFOX4, although a
direct randomised comparison of the two regimens has not been
made. OxMdG is now being further evaluated in the ongoing MRC
CR08 (FOCUS) trial, which compares its use as first-line therapy or
reserved for second-line, and includes a comparison with an
equivalent irinotecan-containing regimen.
ACKNOWLEDGEMENTS
Research supported by Cancer Research UK and the Cookridge
Hospital GI Oncology Research Fund. Oxaliplatin was provided
unconditionally by Sanofi Synthelabo, UK.
Time to progression
Days
720 360 0
P
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
1.0
0.8
0.6
0.4
0.2
0.0
Figure 1 Time to progression, all patients.
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Figure 2 Overall survival, all patients.
Table 3 Comparison of FOLFOX and OxMdG regimes
FOLFOX 4
(De Gramont et al, 2000)
FOLFOX 6
(Tournigand et al, 2001)
OxMdG
(Cheeseman et al, 2002)
OxMdG
(this report)
Total FU dose/cycle (bolus+infusion) 800+1200 400+2400 ( 3000) 400+2400 400+2400
Total oxaliplatin dose/cycle 85 100 85 85
Total colorectal patients 210 113 25 55
Assessable for response 207 109 24 52
Response rate CR+PR 50.7 56 72 53
Median FFS (months) 8.2 8.9 10.6 8.3
Median OS (months) 16.2 Not reported 16.7 14.5
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